EnClear Therapies, Inc

EnClear Therapies, Inc., based in Newburyport, MA, is dedicated to improving and extending the lives of patients suffering from central nervous system (CNS) disorders, including neurodegenerative diseases and CNS malignancies. Utilizing their proprietary EnTrega CSF Platform, the company aims to provide precision dosing for existing next-generation therapeutics, addressing a significant market need in neuro-oncology.

The EnTrega CSF Platform employs closed-loop cerebrospinal fluid control integrated with machine learning and artificial intelligence to enhance therapeutic efficacy while minimizing the risk of severe side effects and peripheral toxicity. By leveraging partnerships, EnClear seeks to expand its portfolio into neurodegenerative lysosomal storage autoimmune diseases, positioning itself at the forefront of integrated neurotechnology.

Generated from the website